'thyroid medicine exporter in washington'

EACH FILM-COATED LUCICABOZ TABLET CONTAINS: Cabozantinib 20mg INDICATION: LuciCaboz a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). DOSAGE AND USE: Recommended Dose: 140 mg orally, once daily. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking LuciCaboz. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

Each LuciPral capsule contains: Pralsetinib ……………………… 100mg INDICATION: LuciPral is a kinase inhibitor indicated for treatment of 1. adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). 2. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy 1 3, Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory DOSAGE AND USE: The recommended dosage in adults and pediatric patients 12 years and older is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking LuciPral). Capsule should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. WARNING: Keep medicine out of the reach of Children. Do not administered LuciLorla in Pregnancy and Lactation patient treatment.

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

COMPOSITION: Each LuciLenva capsule contains: 12.25mg Lenvatinib mesylate equivalent to Lenvatinib.………10mg INDICATION: LuciLenva is a kinase inhibitor that is indicated: 1. For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 2. In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC). 3. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). DOSAGE AND USE: 1. DTC: The recommended dosage is 24 mg orally once daily. 2. RCC: The recommended dosage is 18 mg orally with everolimus 5 mg orally once daily. 3. HCC: The recommended dosage is based on actual body weight: · 12 mg orally once daily for patients greater than or equal to 60 kg · 8 mg orally once daily for patients less than 60 kg. Capsules should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

COMPOSITION: Each LuciLenva capsule contains: 12.25mg Lenvatinib mesylate equivalent to Lenvatinib.………4mg INDICATION: LuciLenva is a kinase inhibitor that is indicated: 1. For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 2. In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC). 3. For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). DOSAGE AND USE: 1. DTC: The recommended dosage is 24 mg orally once daily. 2. RCC: The recommended dosage is 18 mg orally with everolimus 5 mg orally once daily. 3. HCC: The recommended dosage is based on actual body weight: · 12 mg orally once daily for patients greater than or equal to 60 kg · 8 mg orally once daily for patients less than 60 kg. Capsules should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

EACH LUCICRIZ CAPSULE CONTAINS: Crizotinib 250mg INDICATION: LuciCriz is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. DOSAGE AND USE: The recommended dosage is 250 mg orally twice daily. Capsules should be swallowed whole & not chewed or crushed. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

EACH FILM-COATED LUCIELO TABLET CONTAINS: Eltrombopag Olamine equivalent to Eltrombopag free acid 25mg Eltrombopag Olamine equivalent to Eltrombopag free acid 50mg INDICATION: LuciElo is a thrombopoietin receptor agonist indicated for the treatment of 1. thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 2. thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. 3. patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. DOSAGE AND USE: Take on an empty stomach (1 hour before or 2 hours after a meal). Chronic ITP: Initiate LuciElo at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 109/L. Do not exceed 75 mg per day. Chronic Hepatitis C-associated Thrombocytopenia: Initiate LuciElo at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg. Severe Aplastic Anemia: Initiate LuciElo at 50 mg once daily for most patients. Reduce initial dose in patients with hepatic impairment or patients of East Asian ancestry. Adjust to maintain platelet count greater than 50 x 109/L. Do not exceed 150 mg per day. Tablets should be swallowed whole & not chewed or crushed. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

EACH FILM-COATED LUCIELO TABLET CONTAINS: Eltrombopag Olamine equivalent to Eltrombopag free acid 25mg Eltrombopag Olamine equivalent to Eltrombopag free acid 50mg INDICATION: LuciElo is a thrombopoietin receptor agonist indicated for the treatment of 1. thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 2. thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. 3. patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. DOSAGE AND USE: Take on an empty stomach (1 hour before or 2 hours after a meal). Chronic ITP: Initiate LuciElo at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 109/L. Do not exceed 75 mg per day. Chronic Hepatitis C-associated Thrombocytopenia: Initiate LuciElo at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg. Severe Aplastic Anemia: Initiate LuciElo at 50 mg once daily for most patients. Reduce initial dose in patients with hepatic impairment or patients of East Asian ancestry. Adjust to maintain platelet count greater than 50 x 109/L. Do not exceed 150 mg per day. Tablets should be swallowed whole & not chewed or crushed. STORAGE: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

COMPOSITION: Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg INDICATION: LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. LuciTram is indicated, in combination with dabrafenib, for: · the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations. · the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations. · the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. · the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. DOSAGE AND USE: The recommended dosage of LuciTram is 2 mg orally once daily. Take LuciTram at least 1 hour before or at least 2 hours after a meal. Tablet should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 2°C to 8°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED

COMPOSITION: Each capsule contains: Selpercatinib…..………… 40mg INDICATION: LuciSel is a kinase inhibitor indicated for the treatment of: · Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). · Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. · Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) DOSAGE AND USE: Select patients for treatment with LuciSel based on the presence of a RET gene fusion (NSCLC or thyroid) or specific RET gene mutation (MTC). Recommended dosage in adults and pediatric patients 12 years of age or older is based on weight: ·Less than 50 kg: 120 mg orally twice daily ·50 kg or greater: 160 mg orally twice daily Reduce LuciSel dose in patients with severe hepatic impairment. Capsule should be swallowed whole & not chewed or crushed. STORAGE: in a dry place and store at 20°C to 25°C. MANUFACTURED AND MARKETED BY: LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

Price: 0 | Payment Type: | Available: False | COD Available: False | KYC Status: FAILED